Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc.（PHAT）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
phat · 股价预测 · 9 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 9 位华尔街分析师
Buy
9 位分析师
共识
评级分布
12 个月目标价
High
$28.00
Consensus
$24.67
+148.4% upside
Low
$18.00
Median: $28 · Last Close: $9.93
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$24.67
148.4% upside
High Target
$28
182.0%
Low Target
$18
81.3%
Current Price
$9.93
as of today
Based on analyst price targets, the PHAT stock price prediction for the next 12 months ranges from $18 to $28. The consensus PHAT price forecast of $24.67 implies 148.4% upside from the current price of $9.93.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $9.43 | ↓ 5.00% |
1-day model range: $9.36–$9.5. Peak: $9.5 (-5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $13 | +33.1% |
| 2028 | $16 | +57.3% |
| 2029 | $17 | +73.1% |
| 2030 | $18 | +82.6% |
| 2031 | — | +88.2% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PHAT · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-27 | Barclays | Upgrade ↑ | Equal Weight→Overweight |
| 2026-02-27 | Guggenheim | Maintains | Buy→Buy |
| 2025-10-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-09 | Craig-Hallum | Maintains | Buy→Buy |
| 2025-06-06 | Needham | Maintains | Buy→Buy |
| 2025-05-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-02 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2025-05-02 | Guggenheim | Maintains | Buy→Buy |
| 2025-05-02 | Craig-Hallum | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Phathom Pharmaceuticals, Inc. (PHAT) stock. Of the recent 91 rating actions, 3 were upgrades and 2 were downgrades. 9 analysts currently cover PHAT.
分析师推荐趋势
PHAT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$334M
↓ 55.8% YoY
Revenue Next Year
$540M
↑ 61.6% YoY
EPS This Year
$-0.62
EPS Next Year
$1.19
↓ 291.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast PHAT EPS of $-0.62 for the current fiscal year, based on estimates from 3 analysts. The PHAT revenue forecast is $334M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
PHAT 股价预测由两类独立数据源支撑：来自 9 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。PHAT 的共识目标价为 $24.67（+148.4% 上行空间），分析师共识为 Buy。
PHAT 的短期预测（明日）为 $9.43（-5.00%）。 PHAT 对 2027 年的股价预测均值为 $13。 PHAT 对 2030 年的预测区间为 $17–$20。
Phathom Pharmaceuticals, Inc. 在 NASDAQ 上市，代码 PHAT。PHAT 在 2027 年的整体展望偏积极，在覆盖分析师中约 89% 对应 Buy 共识。
常见问题
PHAT 预测 · 8 个问题根据 9 位华尔街分析师，PHAT 的 12 个月平均目标价为 $24.67，最高 $28.00、最低 $18.00。若有图表，中位目标价可在上方查看。相对当前价 $9.93，隐含约 +148.4% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.